EUVIMEDEUVIMED entdecken
Crossref

T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer

Chaoni Cai, Jialing Huang, Jinfeng Li, Saixiang Zheng, Dijin Lin, Chaohui Duan, Ying Xu

Clinical Immunology · 2026-12 · 288 · 110762

DOI: 10.1016/j.clim.2026.110762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2026-12. Verfasst von Chaoni Cai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Peripheral blood T-cell monitoring may predict treatment response and recurrence in breast cancer patients receiving neoadjuvant therapy (NAT). METHODS: The retrospective, single-center study enrolled 210 primary breast cancer patients (2020-2024). Peripheral T-cell subsets (CD69+, HLA-DR+, etc.) and tumor markers (CEA, CA125, etc.) were assessed at baseline, post-NAT, and post-surgery. Receiver operating characteristic (ROC) curves, Logistic and Cox regression, decision curve analysis, longitudinal trajectory analysis, and Gene Set Enrichment Analysis (GSEA) were performed. RESULTS: Baseline CD3+CD69+T /CD3+T and CD3+HLA-DR+T /CD3+T ratios independently predicted pathological complete response (pCR) with a combined AUC of 0.87. Post-NAT Treg /CD4+T and CD3+HLA-DR+T /CD3+T predicted recurrence/metastasis (AUC = 0.85). Post-surgery, the combination of CD3+CD8+HLA-DR+T /CD3+T and CA125 achieved an AUC of 0.88. Post-treatment T-cell activation correlated with improved survival. Three-year trajectory analysis revealed distinct T-cell dynamics between no recurrence/metastasis and recurrence/metastasis patients. GSEA showed CD69-high CD8+T were enriched in inflammatory pathways, whereas HLA-DR-high CD8+T were enriched in cell-cycle, metabolism, and effector pathways. CONCLUSIONS: Peripheral T-cell activation profiles were associated with NAT response and clinical outcomes in this cohort, suggesting their potential as dynamic biomarkers for recurrence/metastasis risk stratification. However, given the retrospective, single-center design and lack of external validation, these internally validated models warrant independent prospective validation prior to clinical application.

Schlagwörter

Stichwörter der Autor:innen

Activated T-cell subsetBreast cancerDynamic monitoringNeoadjuvant therapyPeripheral blood

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Clinical Laboratory, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Ho…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cai, C., Huang, J., Li, J., Zheng, S., Lin, D., Duan, C., & Xu, Y. (2026). T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer. Clinical Immunology, 288, 110762. https://doi.org/10.1016/j.clim.2026.110762

Vancouver

Cai C, Huang J, Li J, Zheng S, Lin D, Duan C, et al. T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer. Clinical Immunology. 2026;288:110762. doi:10.1016/j.clim.2026.110762

BibTeX
@article{Cai2026,
  author = {Cai, Chaoni and Huang, Jialing and Li, Jinfeng and Zheng, Saixiang and Lin, Dijin and Duan, Chaohui and Xu, Ying},
  title = {T-cell activation profiles predict outcomes of neoadjuvant therapy in breast cancer},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {288},
  pages = {110762},
  doi = {10.1016/j.clim.2026.110762}
}
Kostenlos starten →